AR and posterior cortical atrophy: Targeting the AR has drastically improved the prognosis of PCa patients, but a subset of tumors can become AR-indifferent and hence resistant to AR-targeting therapies, thus leading to fatalities through metastatic diseases that are treatment-resistant [3].